Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Beleodaq
Belinostat is a histone deacetylase (HDAC) inhibitor indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). It works by inhibiting HDAC enzymes, which are involved in the regulation of gene expression. This inhibition can lead to the accumulation of acetylated histones and other proteins, resulting in changes in gene expression and ultimately cell death in cancer cells.
Treatment of relapsed or refractory peripheral T-cell lymphoma.
Outcome:
Decreased belinostat levels, reduced efficacy
Mechanism:
Increased metabolism of belinostat
Outcome:
Reduced belinostat absorption
Mechanism:
Chelation or altered gastric pH
Outcome:
May slightly decrease belinostat absorption
Mechanism:
Delayed gastric emptying
Most likely new formulation: oral formulation for improved patient convenience (Year: 2026, 30% confidence)
Based on current usage and clinical trial data, there is a low likelihood of belinostat being withdrawn from the market in the next 5 years (less than 5% predicted probability).
Antineoplastic Agent, HDAC Inhibitor
Hydroxamic Acid